Additional Antigens definition

Additional Antigens has the meaning ascribed to such term in the Option Agreement.
Sample 1Sample 2Sample 3
Additional Antigens means one or more of (a) a Public Domain Antigen, and (b) a Proprietary Antigen; in each of (a) and (b), that is useful to enhance or broaden the immune response against EphA2, and that is determined to be available for inclusion in Products in accordance with Section 2.5.
Sample 1
Additional Antigens means those Corixa Antigens and R&D Program Antigens that are licensed by SB hereunder other than pursuant to Section 5(f).
Sample 1

Examples of Additional Antigens in a sentence

  • Of the 236 cooperative respondents to the survey, 41% of the survey sample come from the financial sector.

  • There are [**] Programme Antigens and [**] Additional Antigens in the Unitary Product.

  • To best show the effect an incandescent light is a necessity, generally aimed at the recording from behind the technician’s shoulder, so that they are looking down the beam of light.

  • There [**] Programme Antigen and [**] Additional Antigens in the Unitary Product, but it has not been launched in France.

  • Award of the price agreement, if awarded, will be made within sixty (60) calendar days after the date of bid opening unless otherwise stated in the Bid Documents.

  • There [**] Programme Antigen and [**] Additional Antigens in the Unitary Product.

Related to Additional Antigens

  • Additional Indication means any indication other than the Initial Indication.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Additional Product means any Product identified as such in the Product Terms and chosen by Enrolled Affiliate under this Enrollment.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Gene Therapy means a product or service for the treatment or prevention of a disease that utilizes ex vivo or in vivo delivery (via viral or nonviral gene transfer methods or systems) of Genetic Material, including any cell incorporating Genetic Material.

  • Initial Indication means the use of a Product for the treatment of opioid addiction.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Additional Products means products, services and applications that are not part of the Services but that may be accessible, via the Admin Console or otherwise, for use with the Services.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Licensed Compound means [***].

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Collaboration Know-How means all Know-How and Materials discovered, created, conceived, developed or reduced to practice in the course of performing activities under the Collaboration Program (whether solely by one Party or jointly by the Parties, in each case with their Affiliates or any Third Parties or any employees, consultants or agents of any of the foregoing which perform activities under the Collaboration Program).

  • Manufacturing Know-How means, with respect to the Product or any Variant thereof, the technology, data, designs, processes, methods, specifications and other know-how used in connection with the formulation, manufacture, labeling, packaging, quality control, release testing, and production of the Product, and all ingredients used therein and portions thereof.

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Development Milestone Event shall have the meaning set forth in Section 9.2(a).